Skip to main content

New insights on CRISPR/Cas9-based therapy for breast Cancer

Abstract

CRISPR/Cas9 has revolutionized genome-editing techniques in various biological fields including human cancer research. Cancer is a multi-step process that encompasses the accumulation of mutations that result in the hallmark of the malignant state. The goal of cancer research is to identify these mutations and correlate them with the underlying tumorigenic process. Using CRISPR/Cas9 tool, specific mutations responsible for cancer initiation and/or progression could be corrected at least in animal models as a first step towards translational applications. In the present article, we review various novel strategies that employed CRISPR/Cas9 to treat breast cancer in both in vitro and in vivo systems.

Introduction

During the past 20 years, several genome-editing technologies have been employed in a wide range of applications. Inspired with bacterial immune system, CRISPR/Cas9 came into existence as a revolutionizing powerful tool that facilitates correction, insertion, or deletion of genetic material both in vitro and in vivo systems. The discovery of this captivating bacterial immune defense mechanism resulted in an unprecedent revolutionary change in medical sciences [1] (Fig. 1). Upon transfecting cells, Cas9/gRNA complex can find its way to the target sequence (with the help of gRNA) to delete or insert a segment of DNA (with the aid of Cas9 enzyme) [2]. This triggers the cellular endogenous repair mechanisms, which might be one of two; first: non-homology end joining (NHEJ), which is an error-prone mechanism that generates indels and can be used to disrupt a specific gene. Second: homology-directed repair (HDR) [3, 4]. When appropriately designed, a donor DNA could be inserted in the cleavage site to serve as a template on which the broken strand being built. The inserted strand might be normal or even contain a targeted mutation.

Fig. 1
figure1

How CRISPR/Cas9 works as immune system in bacteria. When the invader (plasmid or virus) enters bacteria [1], it directs a nuclease called Cas2 to snip a short sequence of the viral genome (spacer) [2] and insert it between two repeats in its CRISPR locus [3]. When this invader type come again [4], the bacteria transcribe its spacer to generate crRNA [5], which will be matured by tracrRNA. Both types of RNA associated with Cas9 [6] will be directed to the invader genome to cleave it (using Cas9) after recognizing it (using crRNA) [7]

Breast cancer is a leading cause of death in females worldwide [5, 6]. Breast cancer rate is rising worldwide with an expansion in forceful neoplasia in women. Around half of the breast malignancy cases and 60% of the deaths are happening in developing countries. There is an extensive distinction in breast cancer rate among Hispanic, Caucasian and Asian women, with Caucasian women being the most astounding and Asian women being the least [7, 8]. Breast cancer research is a hot area in which CRISPR technology is in the core (Fig. 2).

Fig. 2
figure2

Different research and treatment areas of CRISPR/Cas9 in breast cancer

CRISPR/Cas9 takes its place as an essential, efficient, and straightforward tool for cancer research, especially breast cancer [9]. This tool provides a means to insert, correct, and remove the faulty genes in a precise manner. Some limitations are facing applying this technology in all types of cancer; however, advancements are taking place [10].

CRISPR/Cas9: the Nature’s gift

CRISPR is primarily a gift from the Mother Nature, where scientists discovered it as prokaryotic immune system in bacteria and archaea. The work on CRISPR starts in the late 1980s with several landmarks in this long journey (Table 1), however, the foundational publications came in 2012 to demonstrate that a CRISPR system in Streptococcus pyogenes could be used for genome editing, opening a new gate for genome engineering. In these bacteria, Cas9 is responsible for cleaving the invaders’ DNA. Guided by crRNA (CRISPR RNA) and tracrRNA (trans-activating crRNA which will be combined for editing purposes in vitro to produces gRNA), Cas9 can target a specific site in the genome and then produces double strand breaks (DSBs) [32, 33]. The complex composed of Cas9 and gRNA attacks the specific DNA sequence just upstream of the protospacer-adjacent motif (PAM) sequence, NGG (N represents any nucleotide) [34, 35]. Almost 60 and 40% of archaea and bacteria, respectively used CRISPR in the same manner, with minor differences [36]. CRISPR location, in this sense, serves as a memory deposition where the bacteria can store previous viral or plasmid attacks, and then used this information to defend itself against these invaders in the upcoming attacks.

Table 1 The timeline of genome editing groundbreaking achievements

CRISPR/Cas9-based tumor modeling

The classical method to transform a normal cell into malignant one requires multistep process that involve series of mutations to acquire such cells the hallmarks that characterize the malignant phenotype [37,38,39]. With exploiting the power of CRISPR/Cas9, many research groups were able to create such cancer models (Table 2). Truncating APC tumor suppressor gene in gut cells was successful representative for a well-developed early event in colorectal cancer development. The Wnt signaling activators have been removed from the culture medium to select APC-lacking human intestinal stem cells, leading to provoked β-catenin stabilization, and up-regulation of Wnt pathway [48] and [49]. Other approaches involve creating cells with activated KRAS oncogene along with loss-of-function mutation. Furthermore, P53 was also inactivated using CRISPR/Cas9 [50, 51]. Using these approaches, a combination of mutations could also be generated, and then tested in by inoculating these edited cells into immunodeficient mice. This cancer model answers an immense question, whether the cancer-causing mutation occur randomly or in a precise time order.

Table 2 CRISPR/Cas9- based cancer mouse models (reviewed in [40])

Similar strategies have been used to transduce a non-metastatic mouse lung cancer cell line with CRISPR/Cas9 which targets several protein-coding genes along with miRNA precursors. Chen, Peng [52] recorded a massive growth of tumor and lung metastasis upon inoculating the modified cells into immunodeficient mice. By deep sequencing, the team discovered several novel genes whose activation was crucial to tumor growth and metastasis. This approach allows for recapitulating the process of tumor evolution and metastasis, which in turn, might help in designing specific therapies targeting the faulty gene(s) [53].

CRISPR/Cas9-based transcriptome reprogramming

Transcriptional programs control almost all aspects of organism’s life from early developmental stages until death [54]. Cancer, as an abnormal state of the cells has its own specific transcription program, which has been validated by CRISPR in several cancer types including ovarian, and breast carcinomas, where cancer cells were found to display a cell-specific transcription regulation pattern, with epigenetic modulations being the main affecting factors [55, 56]. This program could be disrupted by inhibiting CDK7, which represents a potential therapeutic option for breast cancer, especially estrogen receptor (ER) mutation-mediated endocrine-resistant type. The most impressive feature is that CDK7 inhibition not only prejudices the cell growth of breast cancer, but also the resistance of the estrogen-responsive MCF7 breast cancer cells [57].

Prior CRISPR, ZFNs (zinc finger nucleases) and TALENs (transcription activator-like effector nucleases) were used to activate and suppress genes as a strategy for cancer therapy. A brief comparison between the three major genome editing tools is highlighted in (Table 3). The structure of both tools made them suitable for holding activators and suppressors [58, 59]. For the time being, these activators and suppressors are easily fused to dCas9, a mutation of Cas9 without endonuclease activity. Recently, more dCas9-based transcription activator/suppressors were made available [60]. Aptamers been used for re-programming the epigenome aiming to reactivate the hypermethylated tumor suppressor genes (TSGs) to recover the growth suppressor activity exerted by these TSGs [61, 62]. This strategy works in liver, colon, breast, and lung cancers. This approach is an alternative to epigenetic-modified small molecules/drugs, which might have undesirable side effects. Furthermore, dCas9 was efficiently used for targeted demethylation of BRCA1 promoter using the demethylation domain of TET1—the enzyme that converts 5-mC (5-methylcytosine) into 5-hmC (5-hydroxymethylcytosine)— in cervical and breast cancer cells. CRISPR/Cas9-based epigenome editing was used also to repress interleukin receptors (IL1R1) and tumor necrosis factor α receptor (TNFR1) in human adipose-derived stem cells. This may open the gate to control various kinds of inflammations that accelerate the growth of different types of cancers [63,64,65].

Table 3 Comparison between the three main genome-editing tools

Yet, an array of epigenetics modifiers based on dCas9 is introduced to modify the epigenetics marks as a new way to treat several diseases including cancer.

Editing DNA for cancer therapy

Although CRISPR technology was used in cancer modeling and screening, it also offers a straightforward way to target-specific cancer therapy. Many trials have been conducted using CRISPR to combat this life-threatening disease. E6 and E7 in the HPV have been challenged with CRISPR/Cas9 to induce the apoptotic machinery and inhibit growth in cervix cancer cell line in vitro [66]. Meanwhile, CRISPR/Cas9-mediated deletion of miRNA-binding site located in the UTR (un-translated region) of F1H1—the gene that regulate angiogenesis in NSCLC cells— resulted in recovering the vascular abnormalities that characterize lung cancer [67].

The oncogene HER2 exons are also a target for CRISPR intervention, where a mutation in the exon12 of HER2 resulted in a dominant negative mutant phenotype [68]. The mutant HER2 was found to inhibit the MAPK/ERK axis of HER2 signaling pathway required for the proliferation of breast cancer cells. Controlling breast cancer via CRISPR-mediated editing of HER2 is enhanced in the presence of PARP inhibitors that is involved in DNA repair and cell death [69]. This combinational approach represents a potential therapeutic option for breast cancer.

Genome-wide synthetic lethal CRISPR screens were performed to determine novel as a therapeutic option for treating endocrine resistant breast cancer. CRISPR screens identified a gene which is associated with the response to endocrine therapy in plentiful of clinical studies [70].

To this end, they tried to combine two therapeutic components; ordinary endocrine therapy and an inhibitor for the gene identified by the CRISPR screens to subdue the endocrine resistance either in cell line or patient-derived xenograft models.

Protein degradation in breast cancer

One of the important ways to enhance tumor cell proliferation is the increased activity of protein degradation. Of these protein-degrading enzymes, comes the 26S proteasome, a multi-catalytic enzyme that is responsible for protein degradation including cell cycle regulation and apoptosis-related proteins [71, 72]. In cancer models, it has been indicated that proteasome inhibitors have anticancer and apoptosis-enhancing properties. Furthermore, it sensitizes tumor cells to the extrinsic and intrinsic pro-apoptotic signals. Therefore, proteasome has become a target for antitumor treatments. It has been indicated that breast cancer proliferation is controlled by a site-specific proteasome phosphorylation process [24], and the interfering and disruption of this process might be of value in controlling the disease.

Using CRISPR/Cas9, dual-specificity tyrosine-regulated kinase 2 (DYRK2) knockout (the enzymes that phosphorylate the proteasome components) was established to disrupt tumorigenesis of the proteasome-addicted human breast carcinoma cells in mice [73].

ER-positive breast cancer could be treated via inhibition of estrogen synthesis using aromatase inhibitors (AI) or via tamoxifen and fulvestrant that compete estrogen on ERα. Mutations in ERα such as ERαY537S and ERαD538G results in rendering advanced metastatic breast cancer insensitive to AI and tamoxifen [74]. To validate the effect of these mutations, breast cancer positive ERα model was created using CRISPR/Cas9 in which the wild type version of ERα was replaced with ERαY537S or ERαD538G. These mutant cells are partially resistant to antiestrogen, i.e., it is manifesting estrogen independent. Antiestrogen resistance of the mutant cells was found to be associated with upregulation of the protein response that reduces the ERα degradation [75].

Migration and invasion enhancer (MIEN1) are involved in cancer progression and metastasis of breast cancer. It has been found that increased expression of MIEN1 might enhances tumor migration and metastasis. Using CRISPR/Cas9, a targeted deletion in this gene effectively led to repeal its expression and hence to control the disease spearing. This approach allows us to deeply understand the role MIEN1 plays in carcinogenesis and tumor progression, which might be transformed in the future as a breast cancer therapeutic option [76].

Mutations in PTEN (phosphatase and tensin homolog) gene, are fundamental step in the carcinogenesis process. PTEN is a tumor suppressor gene, involved in the cell cycle regulation and controlling the proliferation rate. Using CRISPR/Cas9, invasive lobular breast carcinoma (ILC)-initiating cells was targeted to disrupt PTEN in mice mammary gland-specific loss of E-cadherin. This approach can be used for rapid in vivo testing of putative tumor suppressor genes underlie ILC [77].

CRISPR-mediated immunotherapy

Molecular subtypes of breast cancer have different characteristics based on which cancerous cells respond to the intrinsic (immune system) or extrinsic (environment) stimuli (Fig. 3). One unique approach to fight breast cancer cells is using a CRISPR/Cas9-edited macrophages in which signal-regulatory protein alpha (SIRP-α) is eliminated. The edited macrophages will be unable to receive the “do not eat me” signal of CD47-SIRPα from the cancer cells leading to destroy it. On the other hand, T cells could be engineered to express a cancer-specific T-cell receptor (TCR). Taking into consideration that the endogenous TCRs might compete with engineered one, endogenous TCR-β was knocked out in the recipient cells via CRISPR/Cas9. The resultant CRISPR-edited T cells were a 1000-fold more sensitive to cancer antigen than normal TCR-transduced T cells [78]. Meanwhile, CAR T cells were edited by CRISPR/Cas9 to generate inhibition-resistant universal CAR T cells [79].

Fig. 3
figure3

The molecular subtypes of breast cancer

Editing cancer epigenome

CRISPR/Cas9-mediated epigenome editing is one of the potential tools to treat several cancers including breast cancer. The gene approach involves the fusion of Cas9 with a transcription repressor/activator for repression and activation, respectively. The Krüppel-associated box (KRAB) is an example, where the fused dCas9-KRAB was capable to induce locus-specific deposition of H3K9me3 at the HS2 enhancer region, resulting in silencing of multiple globin genes in K562 cells [80]. Cancer cells normally contain a wide variety of genetic mutations either in TSGs or in oncogenes [37, 81]. Using CRISPR/Cas9, specific loss-of-function or gain-of-function mutations could be achieved. This approach enables scientists to identity the causative gene in different types of cancers including breast cancer. Targeting these genes might help in controlling the corresponding cancer. Meanwhile, The ER regulator SRC-1 gene plays a central role in the ability of ER tumors to adapt and facilitate metastatic disease progression. SRC-1 coactivates ER to regulate a network of proliferation- and differentiation-associated genes critical to breast cancer progression. Using CRISPR/Cas9-based epigenetic, silencing of SRC-1 resulted in a poor expression of the proliferation- and differentiation-associated genes, which might control the progression of breast cancer and/or tumor metastasis [82].

CRISPR barcoding

Molecular barcoding using mutations induced by Cas9 is an influential method for recording biological information on real time, however, its applications in mammalian systems is relatively limited [83]. Breast cancer progression and proper response to treatments are major aspects being affected with the large count of mutations accumulated in malignant cells [84, 85]. Although its significant clinical impact, few studies have addressed the intratumor heterogeneity to deeply understand the causative genes and along with underlying molecular mechanisms. Several research groups used CRISPR/Cas9 to introduce oncogenic mutation in a subset of cells within a mass population [86]. These targeted mutations were linked with silent mutations that serve as a genetic barcode and can be identified by qPCR. This approach has been used in different malignant cells to introduce nonsense or missense mutations in TP53, resulting in an inactive or a dominant-negative form of this TSG. In this context, current genome editing approaches lack the capability to generate specific alterations with tumor growth-controlling properties making it hard to repair oncogenic mutations. Initial tracing of the edited cells using CRISPR-barcoding overcomes this limitation [87,88,89].

CRISPR/Cas9 limitations and challenges

Drug resistance

One of the most important challenges in breast cancer therapy is the drug resistance [90]. Accordingly, identifying the drug resistance-related genes might set a new stage of treating breast cancer potentially by using CRISPR/Cas9 technique. The main limitation faces CRISPR application in editing these genes is the off-target activity of Cas9. Various approaches were used to tackle this problem, although the defined mechanisms of high specificity of gRNA remains unclear [91, 92].

Different methods have been introduced to screen for the edited alleles created by CRISPR/Cas9. Among these methods the “pop-in/pop-out” established by Kühn and Chu, in which the isolation of edited alleles became easier [93].

One of the biggest limitations of applying CRISPR/Cas9 for clinical treatments is the presence of a type of antigen-specific T-cells works against Cas9. This, of course, limits the activity of the nuclease and, subsequently, the effectiveness of the entire editing process. Furthermore, the immune system can recognize and eliminate the edited cells. Several reviews highlighted the potential immunological concerns of using CRISPR/Cas9 in clinical settings [3, 94,95,96]. However, more studies are needed to elucidate the function of Cas9-specific T-cells during treatment. These studies should also address engineering a type of Cas9 that can escape the host immune system or at least fusing an immune-compromising agent within the Cas9-harboring cassette.

Another challenge is the delivery system that suit the hard-to-transfect cells/tissues. Several non-viral delivery methods are there including using nanoparticles, electroporation, and direct injection. These methods have its own drawbacks where it needs in general large quantities of the prepared plasmids along with tools required.

Viral and bacteriophage-derived vectors represent the easiest way to deliver CRISPR/Cas9 inside the target cells, however, more preclinical studies are mandatory to characterize its level of geno- and cellular toxicity [97]. In addition, the pharmacokinetics and pharmacodynamic properties of the complex must be identified. Some trials have been conducted to effectively deliver CRISPR system into cells including the encapsulation of the system into lipopolymer with cell specific aptamer for cancer-specific targeting. This method appears to be more efficient in CRISPR system delivery compared to the traditional viral and non-viral delivery methods [98]. Furthermore, Wang, Song [4] used CRISPR/Cas9 delivery system comprising PEGylated nanoparticles based on the α-helical polypeptide PPABLG. Supported by the high membrane-penetrating capability of the polypeptide, P-HNPs attained competent cellular internalization and endosomal escape, which is considered an efficient way to system delivery.

Off-targeting

The major challenge facing CRISPR/Cas9-based therapeutics is the off-target possibility, where Cas9 can cleave DNA at unintended sites [99]. To minimize the off-target effects, the design of gRNA should be of high precision, especially the 5′ end sequence composition. Therefore, several algorithms have been introduced in the recent decade to maximize the on-target and minimize the off-target (Table 4). On the other hand, the activity of Cas9 is considered a crucial defining factor that identify the off-target effect [100]. The higher the activity of Cas9, the increased the level of off-targets (due to non-specific cleavage). Thus, adjusting the Cas9 activity might help in reducing the off-target effects. To this end, various studies were conducted to optimize Cas9 activity. One of the ways to produce conditionally expressed Cas9 is to clone the Cas9-encoding gene under the control of tetracycline-responsive element promoter. This might help in controlling the expression of Cas9 in the presence of tetracycline/doxycycline. Furthermore, cloning gRNA under the same promoter was found to be a good alternative to control off-target cleavages [101,102,103].

Table 4 A group of web-based algorithm for gRNA designing

Another effective approach to control the level of Cas9 expression to decrease off-targets is constructing a version of Cas9, which is 4-hydroxytamoxifen-dependent via attaching a hormone-binding domain of the estrogen receptor to Cas9. In this case, Cas9 is released to the cytoplasm in the presence of 4-hydroxytamoxifen leading to control Cas9 activity [104]. Other approaches implicated the self-splicing properties of protein segments “intein” that can excise itself and join the remaining portions with a peptide bond to render Cas9 nuclease active only in the presence of 4-hydroxytamoxifen [34]. Interestingly, these two systems of controlling the expression of Cas9 might be used soon as a tool to design vectors for therapeutic interventions.

Furthermore, target site recognition by Cas9 requires the recognition of a specific short motif (PAM, protospacer recognition motifs). To tackle this problem, an engineered Cas9 derivatives with altered PAM specificities was designed [105]. Meanwhile, a split variant of Cas9 was fused with low expression protein domain. In this composition, Cas9 became active when stimulated with blue light, allowing researchers to control the activity of Cas9 in vitro and in vivo [106].

On-targeting is determined generally by several factors including gRNA physical design, the nuclease structure (Cas9), the ratio of gRNA/Cas9 in the media, and finally the target site uniqueness [107]. Various approaches were introduced to tackle off-targeting problem including down-sizing the gRNAs to 20 bases, which could increase its specificity by 5000-fold [105]. Other approach involves mutating the Cas9 active domain to alter its cleavage function aiming to enforce it to use two-enzyme unite to make double stand break (DSB) [108]. Furthermore, fusing dCas9 with FokI to increase the specificity was suggested [109]. Altering the electric polarity of the Cas9 two domain; HNH and RuvC to reduce off-target editing, was proved to be more specific with reduced off-target score [103]. One research group has tried to introduce the Cas9 in its protein form rather than being inserted as a Cas9-coding DNA in the plasmid might enhance the on-target capacity and reduce off-target mutations [110].

For CRISPR/Cas9 technology to be applied in clinical settings, the challenge of controlling Cas9 activity should be tackled, taking into consideration that the easy and straightforward the approach, the higher the chance to be used as a therapeutic option for many types of cancer, including breast cancer.

Animal studies

Kleinstiver et al. [77] described a novel approach to validate candidate TSGs that have a role on invasive lobular breast carcinoma by intraductal injection of lentiviral vector that encodes CRISPR/Cas9 system, Cre recombinase, or a combination of the two components in female mice with conditional alleles E-cadherin gene. Thier work enables to identify the putative TSG implicated in invasive lobular breast carcinoma in mice.

In the same context, breast cancer-related miRNAs such as miR-23b and miR-27b were knocked out using CRISPR/Cas9 to examine the breast cancer model in vitro and in vivo. In vitro knock out of miR-23b and miR-27b revealed that these miRNAs are oncogenic miRNAs in MCF7 breast cancer cells in mice. Results also indicated that miR-27b could have tumor suppressive activity under certain circumstances [111].

A knock-in mice with Cre-conditional expression of a cytidine base editor was generated to test the utility for precise somatic engineering of missense mutations in breast cancer. A designed sgRNA-encoding vector was delivered to induce point mutation to assess the effect of defined allelic variants on mammary tumorigenesis. This model was successfully applied in a model of TNBC [112]. Other base editing trial in breast cancer was conducted by [113].

Ethical issues

CRISPR/Cas gene editing technologies have emerged as powerful tools in the study of oncogenic transformation [114]. Although its benefits, it can raise persistent ethical concerns [115]. Recently, CRISPR/Cas9 has been picked as favored technique for genome editing because of its high level of straightforwardness along with the requirements of minimal efforts. These properties make this strategy alluring to be utilized by any molecular science lab, yet the issue is that it can be utilized for any reason except if it is managed [116].

One of the main drawbacks of this technology is the Off-target effects that might have several pathogenic consequences [115]. On the other hand, on-targets may also result in a wide range of deletions and genomic rearrangements [117].

Future perspectives

CRISPR/Cas9 is not only a powerful tool to edit genomes in laboratories, but also it can serve as a therapeutic option after ensuring its safety profiles. Prior applying CRISPR/Cas9 directly to human cells, animal cancer models serve as a preclinical platform in which this tool could be used to create models to deeply elucidate the causative genes of such disease. Furthermore, these models could be investigated in parallel to the cancer patients, which make it easy to rapidly identify different resistance mechanisms and to establish new strategies for treating the disease. Furthermore, since Doudna and Charpentier announced that CRISPR technology could be used in lab as an RNA-guided genome editing tool, CRISPR technology became the ideal platform to personalized medicine, where it offers unique opportunity to edit human genome easily and straightforwardly in specific manner. For the time being, CRISPR capable to correct single mutation in human, and with pushing the technology to its upper limits, multiple genes could be corrected, removed, replaced, or inserted in vivo at the same time in one single hit. Applications of CRISPR cover almost all the biological and biomedicine research [41].

Conclusion

CRISPR/Cas9 is a groundbreaking technology that can be used to cure several human diseases including cancer. In this review, we highlight the most advanced CRISPR/Cas9-based approaches to tackle the challenges associated with many types of cancer including breast cancer. Breast cancer is not only caused by genetic mutations but also by epigenetic one, making CRISPR an ideal tool to deal with mutations underlie this disease. Although CRISPR has a profound range of application especially in human diseases, some ethical issues have arisen fearing from the misuse of this technology. The consequentialist arguments mainly seek the balance between potential benefits and risks in ethical considerations. Nonetheless, the use of CRISPR/Cas9 in somatic cells is ethically accepted because of its low risk compared to its benefits. In addition, germline applications for human embryos have high risks compared to its potential benefits, where it may have unknown harmful effects on future offspring. Nevertheless, one can argue that, for example, correcting the faulty version of the MYBPC3 gene that causes hypertrophic cardiomyopathy in fetus might help in the selection of the healthy embryos for implantation as a potential therapeutic intervention to treat monogenic inherited disorders.

Availability of data and materials

All data analyzed and reviewed are included in this article.

Abbreviations

CRISPR:

Clustered Regularly Interspaced Short Palindromic Repeats

Cas9:

CRISPR associated protein 9

NHEJ:

Non-homology end joining

HDR:

Homology-directed repair

tracrRNA:

Trans-activating crRNA

crRNA:

CRISPR RNA

gRNA:

Guide RNA

PAM:

Protospacer-adjacent motif

APC:

Adenomatous polyposis coli

dCas9 :

Inactivated or ‘dead’ Cas9

indels :

Small insertions and deletions

KRAS :

Kirsten rat sarcoma viral oncogene homolog

β-catenin:

Beta-catenin

Wnt:

Wingless/Integrated

miRNA:

MicroRNA

CDK7:

Cyclin-dependent kinase 7

MCF7:

Michigan Cancer Foundation –7

ZFNs:

Zinc finger nucleases

TALENs:

transcription activator-like effector nucleases

BRCA1:

Breast cancer susceptibility gene

TET1:

Ten-Eleven Translocation-1

5-mC:

5-methylcytosine

5-hmC:

5-hydroxymethylcytosine

IL1R1:

Interleukin receptors

TNFR1:

Tumor necrosis factor α receptor

HPV:

Human papillomavirus

UTR :

Un-translated region

NSCLC:

Non-small cell lung cancer

HER2:

Human epidermal growth factor receptor 2

MAPK:

Mitogen-activated protein kinase (MAPK)

ERK:

Extracellular signal-regulated kinase

F1H1:

Distal 59-flanking region F1, haplotype 1

PARP:

Poly(ADP-ribose) polymerase

DYRK2:

Dual-specificity tyrosine-regulated kinase 2

ER:

Estrogen Receptor

AI:

Aromatase inhibitors

MIEN1:

Migration and invasion enhancer

PTEN:

Phosphatase and tensin homolog

ILC:

Invasive lobular breast carcinoma

SIRP-α:

Signal-regulatory protein alpha

CD47-SIRPα:

Cluster differentiation 47- signal-regulatory protein alpha

TCR:

T-cell receptor

CAR T cell:

Chimeric antigen receptor T cell

KRAB:

Krüppel-associated box

H3K9me3:

Histone3 lysin 9 triple methylation

SRC-1 :

Steroid receptor coactivator 1

qPCR:

Quantitative PCR

TP53:

Tumor protein 53

PPABLG:

α-helical polypeptide

P-HNPs:

A PEGylated nanoparticles based on the cationic α-helical polypeptide poly(γ-4-((2-(piperidin-1-yl)ethyl)aminomethyl)benzyl-l-glutamate

DSB:

Double strand break

FokI:

Endonuclease isolated from Flavobacteria okeanokoites I

MYBPC3:

Myosin Binding Protein C, Cardiac

E7:

Early viral protein

References

  1. 1.

    Ratan ZA, Son YJ, Haidere MF, Uddin BMM, Yusuf MA, Bin Zaman S, et al. CRISPR-Cas9: a promising genetic engineering approach in cancer research. Therapeutic Advances Med Oncol. 2018;10:1758834018755089.

    Google Scholar 

  2. 2.

    Katrekar D, Hu M, Mali P. Advances in CRISPR-Cas based genome engineering. Curr Opinion Biomed Eng. 2017;1:78–86. https://doi.org/10.1016/j.cobme.2017.04.001.

    Article  Google Scholar 

  3. 3.

    Chew WL. Immunity to CRISPR Cas9 and Cas12a therapeutics. Wiley Interdisciplinary Reviews: Syst Biol Med. 2018;10(1):n/a.

    CAS  Google Scholar 

  4. 4.

    Wang HX, Song Z, Lao YH, Xu X, Gong J, Cheng D, et al. Nonviral gene editing via CRISPR/Cas9 delivery by membrane-disruptive and endosomolytic helical polypeptide. Proc Natl Acad Sci U S A. 2018;115(19):4903–8. https://doi.org/10.1073/pnas.1712963115.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Gao Y, Widschwendter M, Teschendorff AE. DNA methylation patterns in Normal tissue correlate more strongly with breast Cancer status than copy-number variants. EBioMedicine. 2018;31:243–52. https://doi.org/10.1016/j.ebiom.2018.04.025.

    Article  PubMed  PubMed Central  Google Scholar 

  6. 6.

    DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017, racial disparity in mortality by state: breast Cancer statistics, 2017. CA Cancer J Clin. 2017;67(6):439–48. https://doi.org/10.3322/caac.21412.

    Article  PubMed  Google Scholar 

  7. 7.

    Vogel VG. 15 - Epidemiology of Breast Cancer. In: Bland KI, Copeland EM, Klimberg VS, Gradishar WJ, editors. The Breast (Fifth Edition): Elsevier; 2018. p. 207–18. e4.

    Google Scholar 

  8. 8.

    Jones T, Lockhart JS, Mendelsohn-Victor KE, Duquette D, Northouse LL, Duffy SA, et al. Use of Cancer genetics Services in African-American Young Breast Cancer Survivors. Am J Prev Med. 2016;51(4):427–36. https://doi.org/10.1016/j.amepre.2016.03.016.

    Article  PubMed  Google Scholar 

  9. 9.

    Banerjee B, Sherwood RI. A CRISPR view of gene regulation. Curr Opin Syst Biol. 2017;1:1–8. https://doi.org/10.1016/j.coisb.2016.12.016.

    Article  PubMed  PubMed Central  Google Scholar 

  10. 10.

    Zuckermann M, Kawauchi D, Gronych J. Applications of the CRISPR/Cas9 system in murine cancer modeling. Brief Funct Genomics. 2017;16(1):25–33. https://doi.org/10.1093/bfgp/elw021.

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Ishino Y, Krupovic M, Forterre P. History of CRISPR-Cas from encounter with a mysterious repeated sequence to genome editing technology. J Bacteriol. 2018;200(7).

  12. 12.

    Mojica FJ, Juez G, Rodríguez-Valera F. Transcription at different salinities of Haloferax mediterranei sequences adjacent to partially modified PstI sites. Mol Microbiol. 1993;9(3):613–21. https://doi.org/10.1111/j.1365-2958.1993.tb01721.x.

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    Kim YG, Cha J, Chandrasegaran S. Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc Natl Acad Sci U S A. 1996;93(3):1156–60. https://doi.org/10.1073/pnas.93.3.1156.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  14. 14.

    Smith J, Bibikova M, Whitby FG, Reddy AR, Chandrasegaran S, Carroll D. Requirements for double-strand cleavage by chimeric restriction enzymes with zinc finger DNA-recognition domains. Nucleic Acids Res. 2000;28(17):3361–9. https://doi.org/10.1093/nar/28.17.3361.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Bibikova M, Golic M, Golic KG, Carroll D. Targeted chromosomal cleavage and mutagenesis in Drosophila using zinc-finger nucleases. Genetics. 2002;161(3):1169–75.

    CAS  Article  Google Scholar 

  16. 16.

    Jansen R. Embden JDAv, Gaastra W, Schouls LM. Identification of genes that are associated with DNA repeats in prokaryotes. Mol Microbiol. 2002;43(6):1565–75. https://doi.org/10.1046/j.1365-2958.2002.02839.x.

    CAS  Article  PubMed  Google Scholar 

  17. 17.

    Lloyd A, Plaisier CL, Carroll D, Drews GN. Targeted mutagenesis using zinc-finger nucleases in Arabidopsis. Proc Natl Acad Sci U S A. 2005;102(6):2232–7. https://doi.org/10.1073/pnas.0409339102.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  18. 18.

    Bolotin A, Quinquis B, Sorokin A, Ehrlich SD. Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin. Microbiology. 2005;151(8):2551–61. https://doi.org/10.1099/mic.0.28048-0.

    CAS  Article  PubMed  Google Scholar 

  19. 19.

    Makarova KS, Grishin NV, Shabalina SA, Wolf YI, Koonin EV. A putative RNA-interference-based immune system in prokaryotes: computational analysis of the predicted enzymatic machinery, functional analogies with eukaryotic RNAi, and hypothetical mechanisms of action. Biology direct. 2006;1(1):7.

    Article  Google Scholar 

  20. 20.

    Stan JJB, Jore MM, Lundgren M, Westra ER, Rik JHS, Ambrosius PLS, et al. Small CRISPR RNAs guide antiviral defense in prokaryotes. Science. 2008;321(5891):960–4.

    Article  Google Scholar 

  21. 21.

    Dupuis M-È, Villion M, Fremaux C, Horvath P, Magadán AH, Romero DA, et al. The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature. 2010;468(7320):67–71.

    Article  Google Scholar 

  22. 22.

    Deltcheva E, Chylinski K, Sharma CM, Gonzales K, Chao Y, Pirzada ZA, et al. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature. 2011;471(7340):602–7. https://doi.org/10.1038/nature09886.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  23. 23.

    Gasiunas G, Barrangou R, Horvath P, Siksnys V. Cas9–crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci. 2012;109(39):E2579–86. https://doi.org/10.1073/pnas.1208507109.

    Article  PubMed  Google Scholar 

  24. 24.

    Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E, et al. A programmable dual-RNA—guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816–21. https://doi.org/10.1126/science.1225829.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  25. 25.

    Shalem O, Sanjana NE, Zhang F. High-throughput functional genomics using CRISPR-Cas9. Nat Rev Genet. 2015;16(5):299–311. https://doi.org/10.1038/nrg3899.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  26. 26.

    Zetsche B, Gootenberg Jonathan S, Abudayyeh Omar O, Slaymaker Ian M, Makarova Kira S, Essletzbichler P, et al. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell. 2015;163(3):759–71. https://doi.org/10.1016/j.cell.2015.09.038.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  27. 27.

    Liang P, Xu Y, Zhang X, Ding C, Huang R, Zhang Z, et al. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. 蛋白质与细胞:英文版. 2015;6(5):363–72.

    CAS  PubMed Central  Google Scholar 

  28. 28.

    Regan PM, Langford D, Khalili K. Regulation and functional implications of Opioid receptor splicing in Opioid pharmacology and HIV Pathogenesis: OPIOID RECEPTOR SPLICING IN HIV PATHOGENESIS. J Cell Physiol. 2016;231(5):976–85. https://doi.org/10.1002/jcp.25237.

    CAS  Article  PubMed  Google Scholar 

  29. 29.

    Esvelt K. Gene editing can drive science to openness. Nature. 2016;534(7606):153.

    CAS  Article  Google Scholar 

  30. 30.

    Lee K, Conboy M, Park HM, Jiang F, Kim HJ, Dewitt MA, et al. Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair. Nat Biomed Eng. 2017;1(11):889–901. https://doi.org/10.1038/s41551-017-0137-2.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  31. 31.

    Morales DP, Morgan EN, McAdams M, Chron AB, Shin JE, Zasadzinski JA, et al. Light-Triggered Genome Editing: Cre Recombinase Mediated Gene Editing with Near-Infrared Light. Small. 2018;14(30):e1800543–n/a.

    Article  Google Scholar 

  32. 32.

    Zhang X, Xu L, Fan R, Gao Q, Song Y, Lyu X, et al. Genetic editing and interrogation with Cpf1 and caged truncated pre-tRNA-like crRNA in mammalian cells. Cell Discov. 2018;4(1).

  33. 33.

    Chow RD, Kim HR, Chen S. Programmable sequential mutagenesis by inducible Cpf1 crRNA array inversion. Nat Commun. 2018;9(1).

  34. 34.

    Zhao C, Zhao Y, Zhang J, Lu J, Chen L, Zhang Y, et al. HIT-Cas9: a CRISPR/Cas9 genome editing device under tight and effective drug control. Mol Therap-Nucleic Acids. 2018;13:208–19. https://doi.org/10.1016/j.omtn.2018.08.022.

    CAS  Article  Google Scholar 

  35. 35.

    Ahmad G, Amiji M. Use of CRISPR/Cas9 gene-editing tools for developing models in drug discovery. Drug Discov Today. 2018;23(3):519–33. https://doi.org/10.1016/j.drudis.2018.01.014.

    CAS  Article  PubMed  Google Scholar 

  36. 36.

    Du Toit A. What CRISPR memories are made of: Bacterial genetics. Nat Rev Microbiol. 2015;13(4):185.

    Article  Google Scholar 

  37. 37.

    Raj VS. 29 - Cancer Rehabilitation. In: Cifu DX, Lew HL, editors. Braddom's Rehabilitation Care: A Clinical Handbook: Elsevier; 2018. p. 197–203. e12.

    Chapter  Google Scholar 

  38. 38.

    Autier P. Age at cancer diagnosis and interpretation of survival statistics. Lancet Oncol. 2016;17(7):847–8. https://doi.org/10.1016/S1470-2045(16)30048-1.

    Article  PubMed  Google Scholar 

  39. 39.

    Yang HT, Jaeger M, Walker A, Wei D, Leiker K, Tao WT. Break breast Cancer addiction by CRISPR/Cas9 genome editing. J Cancer. 2018;9(2):219–31. https://doi.org/10.7150/jca.22554.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  40. 40.

    Kannan R, Ventura A. The CRISPR revolution and its impact on cancer research. Swiss Med Wkly. 2015;145:w14230.

    PubMed  PubMed Central  Google Scholar 

  41. 41.

    Sanchez-Rivera FJ, Jacks T. Applications of the CRISPR-Cas9 system in cancer biology. Nat Rev Cancer. 2015;15(7):387–95. https://doi.org/10.1038/nrc3950.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  42. 42.

    Maddalo D, Manchado E, Concepcion CP, Bonetti C, Vidigal JA, Han Y-C, et al. In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature. 2014;516(7531):423–8. https://doi.org/10.1038/nature13902.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  43. 43.

    Malina A, Mills JR, Cencic R, Yan Y, Fraser J, Schippers LM, et al. Repurposing CRISPR/Cas9 for in situ functional assays. Genes Dev. 2013;27(23):2602–14. https://doi.org/10.1101/gad.227132.113.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  44. 44.

    Baliou S, Adamaki M, Kyriakopoulos AM, Spandidos DA, Panayiotidis M, Christodoulou I, et al. CRISPR therapeutic tools for complex genetic disorders and cancer (review). Int J Oncol. 2018;53(2):443–68. https://doi.org/10.3892/ijo.2018.4434.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  45. 45.

    Chiou S-H, Winters IP, Wang J, Naranjo S, Dudgeon C, Tamburini FB, et al. Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing. Genes Dev. 2015;29(14):1576–85. https://doi.org/10.1101/gad.264861.115.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  46. 46.

    Chen F, Wang Y, Yuan Y, Zhang W, Ren Z, Jin Y, et al. Generation of B cell-deficient pigs by highly efficient CRISPR/Cas9-mediated gene targeting. J Genet Genom = Yi chuan xue bao. 2015;42(8):437–44.

    CAS  Article  Google Scholar 

  47. 47.

    Antal C, Hudson A, Kang E, Zanca C, Wirth C, Stephenson N, et al. Cancer-associated protein kinase C mutations reveal Kinase's role as tumor suppressor. Cell. 2014;160(3):489–502.

    Article  Google Scholar 

  48. 48.

    Matano M, Date S, Shimokawa M, Takano A, Fujii M, Ohta Y, et al. Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat Med. 2015;21(3):256–62. https://doi.org/10.1038/nm.3802.

    CAS  Article  PubMed  Google Scholar 

  49. 49.

    Drost J, van Boxtel R, Blokzijl F, Mizutani T, Sasaki N, Sasselli V, et al. Use of CRISPR-modified human stem cell organoids to study the origin of mutational signatures in cancer. Science. 2017;358(6360):234.

    CAS  Article  Google Scholar 

  50. 50.

    Lee W, Lee JH, Jun S, Bang D. Selective targeting of KRAS oncogenic alleles by CRISPR/Cas9 inhibits proliferation of cancer cells. Sci Rep. 2018;8(1):11879–7. https://doi.org/10.1038/s41598-018-30205-2.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  51. 51.

    Kim W, Lee S, Kim HS, Song M, Cha YH, Kim Y-H, et al. Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth. Genome Res. 2018;28(3):374–82. https://doi.org/10.1101/gr.223891.117.

    CAS  Article  PubMed Central  Google Scholar 

  52. 52.

    Chen L, Peng M, Li N, Song Q, Yao Y, Xu B, et al. Combined use of EpCAM and FRα enables the high-efficiency capture of circulating tumor cells in non-small cell lung cancer. Scientific Rep. 2018;8(1).

  53. 53.

    Chen S, Sanjana Neville E, Zheng K, Shalem O, Lee K, Lee H, et al. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell. 2015;160(6):1246–60. https://doi.org/10.1016/j.cell.2015.02.038.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  54. 54.

    Takaku M, Grimm SA, Roberts JD, Chrysovergis K, Bennett BD, Myers P, et al. GATA3 zinc finger 2 mutations reprogram the breast cancer transcriptional network. Nat Commun. 2018;9(1).

  55. 55.

    Linde N, Casanova-Acebes M, Sosa MS, Mortha A, Rahman A, Farias E, et al. Macrophages orchestrate breast cancer early dissemination and metastasis. Nat Commun. 2018;9(1).

  56. 56.

    Zhang Z, Christin JR, Wang C, Ge K, Oktay MH, Guo W. Mammary-stem-cell-based somatic mouse models reveal breast Cancer drivers causing cell fate Dysregulation. Cell Rep. 2016;16(12):3146–56. https://doi.org/10.1016/j.celrep.2016.08.048.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  57. 57.

    Wang Y, Wang Zhigang C, Zhang T, Kwiatkowski N, Abraham Brian J, Lee Tong I, et al. CDK7-dependent transcriptional addiction in triple-negative breast Cancer. Cell. 2015;163(1):174–86. https://doi.org/10.1016/j.cell.2015.08.063.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  58. 58.

    Ain QU, Chung JY, Kim Y-H. Current and future delivery systems for engineered nucleases: ZFN, TALEN and RGEN. J Control Release. 2015;205:120–7. https://doi.org/10.1016/j.jconrel.2014.12.036.

    CAS  Article  Google Scholar 

  59. 59.

    Gupta RM, Musunuru K. Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9. J Clin Invest. 2014;124(10):4154–61. https://doi.org/10.1172/JCI72992.

    Article  PubMed  PubMed Central  Google Scholar 

  60. 60.

    Xu X, Qi LS. A CRISPR–dCas toolbox for genetic engineering and synthetic biology. J Mol Biol. 2019;431(1):34–47.

  61. 61.

    Catuogno S, Esposito CL, Ungaro P, de Franciscis V. Nucleic Acid Aptamers Targeting Epigenetic Regulators: An Innovative Therapeutic Option. Pharmaceuticals (Basel, Switzerland). 2018;11(3):79.

    CAS  Article  Google Scholar 

  62. 62.

    Spitale RC, Tsai M-C, Chang HY. RNA templating the epigenome: long noncoding RNAs as molecular scaffolds. Epigenetics. 2011;6(5):539–43. https://doi.org/10.4161/epi.6.5.15221.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  63. 63.

    Farhang N, Brunger JM, Stover JD, Thakore PI, Lawrence B, Guilak F, et al. CRISPR-based Epigenome editing of cytokine receptors for the promotion of cell survival and tissue deposition in inflammatory environments. Tissue Eng A. 2017;23(15–16):738–49. https://doi.org/10.1089/ten.tea.2016.0441.

    CAS  Article  Google Scholar 

  64. 64.

    Qin W, Xiong Y, Chen J, Huang Y, Liu T. DC-CIK cells derived from ovarian cancer patient menstrual blood activate the TNFR1-ASK1-AIP1 pathway to kill autologous ovarian cancer stem cells. J Cell Mol Med. 2018;22(7):3364–76. https://doi.org/10.1111/jcmm.13611.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  65. 65.

    Xu H, Sun Q, Lu J, Lu L, Luo F, Zhou L, et al. MicroRNA-218 acts by repressing TNFR1-mediated activation of NF-κB, which is involved in MUC5AC hyper-production and inflammation in smoking-induced bronchiolitis of COPD. Toxicol Lett. 2017;280:171–80. https://doi.org/10.1016/j.toxlet.2017.08.079.

    CAS  Article  PubMed  Google Scholar 

  66. 66.

    Kennedy EM, Kornepati AVR, Goldstein M, Bogerd HP, Poling BC, Whisnant AW, et al. Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease. J Virol. 2014;88(20):11965–72. https://doi.org/10.1128/JVI.01879-14.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  67. 67.

    Moses C, Garcia-Bloj B, Harvey AR, Blancafort P. Hallmarks of cancer: the CRISPR generation. Eur J Cancer. 2018;93:10–8. https://doi.org/10.1016/j.ejca.2018.01.002.

    CAS  Article  PubMed  Google Scholar 

  68. 68.

    Wang C, Zou J, Ma X, Wang E, Peng G. Mechanisms and implications of ADAR-mediated RNA editing in cancer. Cancer Lett. 2017;411:27–34. https://doi.org/10.1016/j.canlet.2017.09.036.

    CAS  Article  PubMed  Google Scholar 

  69. 69.

    Jubin T, Kadam A, Jariwala M, Bhatt S, Sutariya S, Gani AR, et al. The PARP family: insights into functional aspects of poly (ADP-ribose) polymerase-1 in cell growth and survival. Cell Prolif. 2016;49(4):421–37. https://doi.org/10.1111/cpr.12268.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  70. 70.

    Advani SM, Advani P, DeSantis SM, Brown D, VonVille HM, Lam M, et al. Clinical, pathological, and molecular characteristics of CpG Island Methylator phenotype in colorectal Cancer: a systematic review and meta-analysis. Transl Oncol. 2018;11(5):1188–201. https://doi.org/10.1016/j.tranon.2018.07.008.

    Article  PubMed  PubMed Central  Google Scholar 

  71. 71.

    Banerjee S, Ji C, Mayfield JE, Goel A, Xiao J, Dixon JE, et al. Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2. Proc Natl Acad Sci U S A. 2018;115(32):8155–60. https://doi.org/10.1073/pnas.1806797115.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  72. 72.

    Chen L, Zhu G, Johns EM, Yang X, et al. Nat Commun. 2018;9(1).

  73. 73.

    Guo X, Wang X, Wang Z, Banerjee S, Yang J, Huang L, et al. Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis. Nat Cell Biol. 2016;18(2):202–12. https://doi.org/10.1038/ncb3289.

    CAS  Article  PubMed  Google Scholar 

  74. 74.

    Pavlin M, Spinello A, Pennati M, Zaffaroni N, Gobbi S, Bisi A, et al. A Computational Assay of Estrogen Receptor α Antagonists Reveals the Key Common Structural Traits of Drugs Effectively Fighting Refractory Breast Cancers. Scientific Rep. 2018;8(1).

  75. 75.

    Fang Z, Yi Y, Shi G, Li S, Chen S, Lin Y, et al. Role of Brf1 interaction with ERα, and significance of its overexpression, in human breast cancer. Mol Oncol. 2017;11(12):1752–67. https://doi.org/10.1002/1878-0261.12141.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  76. 76.

    Van Treuren T, Vishwanatha JK. CRISPR deletion of MIEN1 in breast cancer cells. PLoS One. 2018;13(10):e0204976. https://doi.org/10.1371/journal.pone.0204976.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  77. 77.

    Annunziato S, Kas SM, Nethe M, Yücel H, Del Bravo J, Pritchard C, et al. Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland. Genes Dev. 2016;30(12):1470–80. https://doi.org/10.1101/gad.279190.116.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  78. 78.

    Russ A, Hua AB, Montfort WR, Rahman B, Riaz IB, Khalid MU, et al. Blocking “don't eat me” signal of CD47-SIRPα in hematological malignancies, an in-depth review. Blood Rev. 2018;32(6):480–9. https://doi.org/10.1016/j.blre.2018.04.005.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  79. 79.

    Fan P, He ZY, Xu T, Phan K, Chen GG, Wei YQ. Exposing cancer with CRISPR-Cas9: from genetic identification to clinical therapy. Transl Cancer Res. 2018;7(3):817–27. https://doi.org/10.21037/tcr.2018.06.16.

    CAS  Article  Google Scholar 

  80. 80.

    Thakore PI, D'Ippolito AM, Song L, Safi A, Shivakumar NK, Kabadi AM, et al. Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements. Nat Methods. 2015;12(12):1143–9. https://doi.org/10.1038/nmeth.3630.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  81. 81.

    O'Donnell KA. Advances in functional genetic screening with transposons and CRISPR/Cas9 to illuminate cancer biology. Curr Opin Genet Dev. 2018;49:85–94. https://doi.org/10.1016/j.gde.2018.03.006.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  82. 82.

    Ward E, Varešlija D, Charmsaz S, Fagan A, Browne AL, Cosgrove N, et al. Epigenome-wide SRC-1–mediated gene silencing represses cellular differentiation in advanced breast Cancer. Clin Cancer Res. 2018;24(15):3692–703. https://doi.org/10.1158/1078-0432.CCR-17-2615.

    CAS  Article  PubMed  Google Scholar 

  83. 83.

    Kalhor R, Mali P, Church GM, et al. Nat Methods. 2017;14(2):195 U6 - ctx_ver=Z3988–2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummonserialssolutionscom&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rftgenre=article&rftatitle=Rapidly+evolving+homing+CRISPR+barcodes&rftjtitle=Nature+methods&rftau=Kalhor%2C+Reza&rftau=Mali%2C+Prashant&rftau=Church%2C+George+M&rftdate=2017-02-01&rfteissn=1548–7105&rftvolume=14&rftissue=2&rftspage=195&rft_id=info%3Apmid%2F27918539&rftexternalDocID=27918539&paramdict=en-US U7 - Journal Article.

    CAS  Article  Google Scholar 

  84. 84.

    Kozak D, Głowacka-Mrotek I, Nowikiewicz T, Siedlecki Z, Hagner W, Sowa M, et al. Analysis of undesirable Sequelae of sentinel node surgery in breast Cancer patients – a prospective cohort study. Pathol Oncol Res. 2018;24(4):891–7. https://doi.org/10.1007/s12253-017-0306-3.

    Article  PubMed  Google Scholar 

  85. 85.

    Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau HT, Forero-Torres A, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study. Breast Cancer Res Treat. 2018;167(3):671–86. https://doi.org/10.1007/s10549-017-4537-5.

    CAS  Article  PubMed  Google Scholar 

  86. 86.

    Chen Y, Zhang Y. Application of the CRISPR/Cas9 System to Drug Resistance in Breast Cancer. Advanc Sci. 2018;5(6).

  87. 87.

    Hill AJ, McFaline-Figueroa JL, Starita LM, Gasperini MJ, Matreyek KA, Packer J, et al. On the design of CRISPR-based single-cell molecular screens. Nat Methods. 2018;15(4):271–4. https://doi.org/10.1038/nmeth.4604.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  88. 88.

    Hegde M, Strand C, Hanna RE, Doench JG. Uncoupling of sgRNAs from their associated barcodes during PCR amplification of combinatorial CRISPR screens. PloS one. 2018;13(5).

  89. 89.

    McKenna A, Findlay GM, Gagnon JA, Horwitz MS, Schier AF, Shendure J. Whole-organism lineage tracing by combinatorial and cumulative genome editing. Science (New York, NY). 2016;353(6298):aaf7907.

    Article  Google Scholar 

  90. 90.

    Moiseenko F, Volkov N, Bogdanov A, Dubina M, Moiseyenko V. Resistance mechanisms to drug therapy in breast cancer and other solid tumors: An opinion. F1000Res. 2017;6:288.

    Article  Google Scholar 

  91. 91.

    Oppel F, Schürmann M, Goon P, Albers AE, Sudhoff H. Specific targeting of oncogenes using CRISPR technology. Cancer Res. 2018;78(19):5506–12. https://doi.org/10.1158/0008-5472.CAN-18-0571.

    CAS  Article  PubMed  Google Scholar 

  92. 92.

    Schmelas C, Grimm D. Split Cas9, Not Hairs − Advancing the Therapeutic Index of CRISPR Technology. Biotechnol J. 2018;13(9).

  93. 93.

    Kühn R, Chu VT. Pop in, pop out: a novel gene-targeting strategy for use with CRISPR-Cas9. Genome Biol. 2015;16(1):244. https://doi.org/10.1186/s13059-015-0810-2.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  94. 94.

    Mollanoori H, Shahraki H, Rahmati Y, Teimourian S. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment. Hum Immunol. 2018;79(12):876–82. https://doi.org/10.1016/j.humimm.2018.09.007.

    CAS  Article  PubMed  Google Scholar 

  95. 95.

    Hochheiser K, Kueh AJ, Gebhardt T, Herold MJ. CRISPR/Cas9: a tool for immunological research. Eur J Immunol. 2018;48(4):576–83. https://doi.org/10.1002/eji.201747131.

    CAS  Article  PubMed  Google Scholar 

  96. 96.

    Montano A, Forero-Castro M, Hernandez-Rivas JM, Garcia-Tunon I, Benito R. Targeted genome editing in acute lymphoblastic leukemia: a review. BMC Biotechnol. 2018;18(1):45–10. https://doi.org/10.1186/s12896-018-0455-9.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  97. 97.

    Modell JW, Jiang W, Marraffini LA. CRISPR-Cas systems exploit viral DNA injection to establish and maintain adaptive immunity. Nature. 2017;544(7648):101–4. https://doi.org/10.1038/nature21719.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  98. 98.

    Liang C, Li F, Li J, Wang C, Wang L, Zhang G, et al. Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma. Biomaterials. 2017;147:68–85. https://doi.org/10.1016/j.biomaterials.2017.09.015.

    CAS  Article  PubMed  Google Scholar 

  99. 99.

    Jubair L, McMillan NAJ. The therapeutic potential of CRISPR/Cas9 Systems in Oncogene-Addicted Cancer Types: virally driven cancers as a model system. Mol Therap - Nucleic Acids. 2017;8:56–63. https://doi.org/10.1016/j.omtn.2017.06.006.

    CAS  Article  Google Scholar 

  100. 100.

    Gong S, Yu HH, Johnson KA, Taylor DW. DNA unwinding is the primary determinant of CRISPR-Cas9 activity. Cell Rep. 2018;22(2):359–71. https://doi.org/10.1016/j.celrep.2017.12.041.

    CAS  Article  PubMed  Google Scholar 

  101. 101.

    Xiao A, Cheng Z, Kong L, Zhu Z, Lin S, Gao G, et al. CasOT: a genome-wide Cas9/gRNA off-target searching tool. Bioinformatics. 2014;30(8):1180–2. https://doi.org/10.1093/bioinformatics/btt764.

    CAS  Article  PubMed  Google Scholar 

  102. 102.

    Iyer V, Boroviak K, Thomas M, Doe B, Riva L, Ryder E, et al. No unexpected CRISPR-Cas9 off-target activity revealed by trio sequencing of gene-edited mice. PLoS Genet. 2018;14(7).

  103. 103.

    Kimberland ML, Hou W, Alfonso-Pecchio A, Wilson S, Rao Y, Zhang S, et al. Strategies for controlling CRISPR/Cas9 off-target effects and biological variations in mammalian genome editing experiments. J Biotechnol. 2018;284:91–101. https://doi.org/10.1016/j.jbiotec.2018.08.007.

    CAS  Article  PubMed  Google Scholar 

  104. 104.

    Liu C, Zhang L, Liu H, Cheng K. Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications. J Control Release. 2017;266:17–26. https://doi.org/10.1016/j.jconrel.2017.09.012.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  105. 105.

    Kleinstiver BP, Pattanayak V, Prew MS, Tsai SQ, Nguyen NT, Zheng Z, et al. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature. 2016;529(7587):490–5. https://doi.org/10.1038/nature16526.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  106. 106.

    Chira S, Gulei D, Hajitou A, Zimta A-A, Cordelier P, Berindan-Neagoe I. CRISPR/Cas9: transcending the reality of genome editing. Mol Therap - Nucleic Acids. 2017;7:211–22. https://doi.org/10.1016/j.omtn.2017.04.001.

    CAS  Article  Google Scholar 

  107. 107.

    Klose RJ, Cooper S, Farcas AM, Blackledge NP, Brockdorff N. Chromatin sampling-an emerging perspective on targeting Polycomb repressor proteins. PLoS Genet. 2013;9(8):e1003717. https://doi.org/10.1371/journal.pgen.1003717.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  108. 108.

    Hay EA, Khalaf AR, Marini P, Brown A, Heath K, Sheppard D, et al. An analysis of possible off target effects following CAS9/CRISPR targeted deletions of neuropeptide gene enhancers from the mouse genome. Neuropeptides. 2017;64:101–7. https://doi.org/10.1016/j.npep.2016.11.003.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  109. 109.

    Havlicek S, Shen Y, Alpagu Y, Bruntraeger MB, Zufir NB, Phuah ZY, et al. Re-engineered RNA-guided FokI-nucleases for improved genome editing in human cells. Mol Therap. 2017;25(2):342–55. https://doi.org/10.1016/j.ymthe.2016.11.007.

    CAS  Article  Google Scholar 

  110. 110.

    Zhang X-H, Tee LY, Wang X-G, Huang Q-S, Yang S-H. Off-target effects in CRISPR/Cas9-mediated genome engineering. Mol Therap - Nucleic Acids. 2015;4(11):e264. https://doi.org/10.1038/mtna.2015.37.

    CAS  Article  Google Scholar 

  111. 111.

    Hannafon BN, Cai A, Calloway CL, Xu YF, Zhang R, Fung KM, et al. miR-23b and miR-27b are oncogenic microRNAs in breast cancer: evidence from a CRISPR/Cas9 deletion study. BMC cancer. 2019;19(1):642.

    Article  Google Scholar 

  112. 112.

    Annunziato S, Lutz C, Henneman L, Bhin J, Wong K, Siteur B, et al. In situ CRISPR-Cas9 base editing for the development of genetically engineered mouse models of breast cancer. EMBO J. 2020;39(5):e102169. https://doi.org/10.15252/embj.2019102169.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  113. 113.

    Campbell KJ, Blyth K. Somatic base editing to model oncogenic drivers in breast cancer. Lab Anim (NY). 2020;49(4):115–6. https://doi.org/10.1038/s41684-020-0510-8.

    Article  Google Scholar 

  114. 114.

    Albitar A, Rohani B, Will B, Yan A, Gallicano GI. The application of CRISPR/Cas technology to efficiently model complex Cancer genomes in stem cells. J Cell Biochem. 2018;119(1):134–40. https://doi.org/10.1002/jcb.26195.

    CAS  Article  PubMed  Google Scholar 

  115. 115.

    Bailey J. CRISPR-mediated gene editing: scientific and ethical issues. Trends Biotechnol. 2019;37(9):920–1. https://doi.org/10.1016/j.tibtech.2019.05.002.

    CAS  Article  PubMed  Google Scholar 

  116. 116.

    Bartkowski B, Theesfeld I, Pirscher F, Timaeus J. Snipping around for food: economic, ethical and policy implications of CRISPR/Cas genome editing. Geoforum. 2018;96:172–80. https://doi.org/10.1016/j.geoforum.2018.07.017.

    Article  Google Scholar 

  117. 117.

    Haapaniemi E, Botla S, Persson J, Schmierer B, Taipale J. CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response. Nat Med. 2018;24(7):927–30. https://doi.org/10.1038/s41591-018-0049-z.

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgements

Not Applicable.

Funding

This work has not received any funds from any funding bodies.

Author information

Affiliations

Authors

Contributions

HS: conceptualized the idea and wrote the manuscript, SA, HT, and AA revised the manuscript, EC drew the figures and illustrations, FA and AfA collected the data. The author(s) read and approved the final manuscript.

Corresponding author

Correspondence to Hussein Sabit.

Ethics declarations

Ethics approval and consent to participate

Not Applicable.

Consent for publication

All authors confirm their participation and approve the submission.

Competing interests

The authors declare no conflict of interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sabit, H., Abdel-Ghany, S., Tombuloglu, H. et al. New insights on CRISPR/Cas9-based therapy for breast Cancer. Genes and Environ 43, 15 (2021). https://doi.org/10.1186/s41021-021-00188-0

Download citation

Keywords

  • CRISPR/Cas9
  • Genome editing
  • Breast Cancer
  • Therapy